ASH 2023 | Analysis of clinical outcomes & HRU in patients with AML treated with venetoclax vs other therapies

Aaron Goldberg, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses a real-world multi-center study investigating clinical outcomes and healthcare resource utilization (HRU) in patients with newly diagnosed acute myeloid leukemia (AML) unfit for high-intensity chemotherapy. In this study, the outcomes of patients treated with venetoclax-based regimens were compared to patients treated with non-venetoclax-based regimens. Results suggest that the outcomes of patients in the real-world setting are similar to those observed in clinical trials. Interestingly, there was a significant difference observed in HRU, as patients treated with venetoclax and azacitidine spent less time in hospital than those treated with non-venetoclax-based regimens. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.